Sabine Seefried, Anastasia Barcic, Maria Fernanda Grijalva Yepez, Lena Reinhardt, Luise Appeltshauser, Kathrin Doppler, Nurcan Üçeyler, Claudia Sommer
{"title":"Autoantibodies in patients with fibromyalgia syndrome.","authors":"Sabine Seefried, Anastasia Barcic, Maria Fernanda Grijalva Yepez, Lena Reinhardt, Luise Appeltshauser, Kathrin Doppler, Nurcan Üçeyler, Claudia Sommer","doi":"10.1097/j.pain.0000000000003535","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>The objective of this study was to assess the frequency of IgG autoantibodies in patients with fibromyalgia syndrome (FMS), to characterize their binding to dorsal root ganglion (DRG) neurons and glial cells, and to assess whether specific DRG binding patterns correlate with clinical symptoms. Sera of a cohort of 184 patients with FMS and 55 control sera were used to test binding of patient IgG on rat DRG sections. ELISA, Western blot, and preadsorption tests were used to search for potential target antigens. We found binding to DRGs in 68 of 184 FMS sera and in none of the control sera. We could identify 9 binding clusters including binding to neurons and to cells labelled with the satellite glial cell marker fatty acid binding protein 7 (FABP7). Current pain intensity correlated positively with IgG binding to FABP7 immunoreactive structures, and burning pain was associated with binding to transient receptor potential vanilloid 1 immunoreactive neurons. Specific antibody detection revealed 13 of 68 sera positive for anti-citrullinated peptide antibodies, 9 of 68 positive for SOX1 antibodies, 7 of 68 positive for antibodies against the serotonin receptor 5HT1AR, and 3 of 68 positive for fibroblast growth factor 3 antibodies. Our findings support the notion of an immune activation in a subgroup of patients with FMS.</p>","PeriodicalId":19921,"journal":{"name":"PAIN®","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PAIN®","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/j.pain.0000000000003535","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: The objective of this study was to assess the frequency of IgG autoantibodies in patients with fibromyalgia syndrome (FMS), to characterize their binding to dorsal root ganglion (DRG) neurons and glial cells, and to assess whether specific DRG binding patterns correlate with clinical symptoms. Sera of a cohort of 184 patients with FMS and 55 control sera were used to test binding of patient IgG on rat DRG sections. ELISA, Western blot, and preadsorption tests were used to search for potential target antigens. We found binding to DRGs in 68 of 184 FMS sera and in none of the control sera. We could identify 9 binding clusters including binding to neurons and to cells labelled with the satellite glial cell marker fatty acid binding protein 7 (FABP7). Current pain intensity correlated positively with IgG binding to FABP7 immunoreactive structures, and burning pain was associated with binding to transient receptor potential vanilloid 1 immunoreactive neurons. Specific antibody detection revealed 13 of 68 sera positive for anti-citrullinated peptide antibodies, 9 of 68 positive for SOX1 antibodies, 7 of 68 positive for antibodies against the serotonin receptor 5HT1AR, and 3 of 68 positive for fibroblast growth factor 3 antibodies. Our findings support the notion of an immune activation in a subgroup of patients with FMS.
期刊介绍:
PAIN® is the official publication of the International Association for the Study of Pain and publishes original research on the nature,mechanisms and treatment of pain.PAIN® provides a forum for the dissemination of research in the basic and clinical sciences of multidisciplinary interest.